AAD Annual Meeting - American Academy of Dermatology Annual Meeting

Results of the POETYK PsA-2 trial indicate deucravacitinib’s effectiveness at reducing the severity and burden of symptoms in patients with psoriatic arthritis.

Icotrokinra, an oral pill that blocks the IL-23 receptor, had a favorable safety profile in adults and adolescents 12 years and older with moderate-to-severe plaque psoriasis.

Compared to placebo, risankizumab significantly reduced symptom severity for patients with moderate to severe disease.

The findings suggest that ruxolitinib cream could aid itch, pain, and sleep disturbance.

This treatment improved the severity of symptoms in patients with scalp and nail psoriasis.

Findings originate from phase 3 data that was recently presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

The cream significantly reduced abscesses and inflammatory nodules, reaffirming its efficacy as a maintenance option for HS.

Secukinumab affects levels of inflammatory biomarkers, and monitoring levels can help investigators understand how patients are responding to treatment.

In addition, the length of hospital admissions were greater in patients with hidradenitis suppurativa-associated cutaneous squamous cell carcinoma compared to other admissions.

The biosimilarity was evident between SB17 (Samsung Bioepis), ustekinumab (Stelara; Janssen Immunology), and those switching from ustekinumab to SB17.